BIOAGE Labs

NSQ:BIOA · US09077V1008

PharmaceuticalsSmall

360

Value42

Profit price82

Cash yield1

Sales & asset price74

Price/Sales78

Price/Book69

Quality26

Returns on capital25

Return on Capital25

Cash Return on Capital24

Return on Equity27

Profit margins10

Cash backing12

Accruals15

Owner Earnings Margin8

Growth61

Sales growth100

Profit growth59

Reinvestment71

Price momentum84

Safety37

Debt load67

Debt serviceability28

Refinancing55

Debt Payback1

Liquidity25

Sentiment55

Analyst ratings9

Expectations trend95

Opinion Changes98

Price Target Upside91

Market mood41

Value Creation8/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

BIOAGE Labs clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2015

Employees89

Websitebioagelabs.com

ISINUS09077V1008

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

OphthalmologyArtificial IntelligenceEndocrinologyDiabetesCardiovascularInflammationObesityChronic DiseasesBiopharmaBiotechnologyComputerTherapeutics

Description

BioAge Labs, Inc., a biopharmaceutical company, develops therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform, and differentiated human datasets enable it to identify promis…

Analysis

Weak and unloved

BioAge Labs, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is stretched. The company scores 8/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare BIOAGE Labs with its peers

Viking Therapeutics

NAQ:VKTX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tharimmune

NAQ:THAR

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

BridgeBio Oncology Therapeutics

NMQ:BBOT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Acrivon Therapeutics

NMQ:ACRV

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Biomea Fusion

NSQ:BMEA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Sagimet Biosciences

NMQ:SGMT

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →